Why Patent Trolling Threatens Biopharma

Episode Summary

Executive Summary: This episode examines Robin Feldman and Nicholson Price’s warning that biopharma is not immune to patent trolling. Feldman argues that non-practicing entities are expanding beyond tech into life sciences, enabled by broad university-held patents, regulatory barriers to invent-around, and the economics of litigation. She urges universities and policymakers to tighten patent-system loopholes before the problem scales.

Main Topics: Patent trolling as a growing business model (Priority: 5/5): Feldman defines patent trolling (non-practicing entity behavior) as buying and aggregating patents to extract settlements through litigation rather than product development, harming companies across sectors. Why biopharma has seemed protected (Priority: 4/5): The transcript outlines the conventional view that life sciences are less vulnerable because development is slower, more expensive, patents are narrower, and there are fewer targets than in tech. University patents as a potential source of ammunition (Priority: 5/5): Feldman and Price examined patents from major research universities and found many that could be repurposed against existing biopharma products, raising the risk that university portfolios could feed NPEs. Three flawed assumptions about biopharma immunity (Priority: 5/5): She challenges the ideas that biopharma can easily invent around, that patent disputes are primarily about patent validity, and that trolls will only target the most lucrative markets. Regulatory and commercial vulnerability near FDA approval (Priority: 4/5): Because companies are difficult to redesign around after years of development and near-approval milestones, they can be especially exposed to settlement pressure from NPEs. Policy and ethical responsibilities for universities (Priority: 4/5): Feldman argues universities should be cautious about selling patents to monetizers because publicly funded inventions and academic institutions face reputational and financial risks if troll activity grows.

Key Arguments: NPE activity has surged, making patent trolling a significant and expanding threat rather than a niche problem. Biopharma’s long development cycle does not eliminate vulnerability; it can create high-pressure moments that make settlement more likely. Broad university patents on drug formulas, treatment methods, dosing, and research methods could become usable against current products. The patent-trolling model depends less on actual infringement and more on exploiting litigation costs and uncertainty. As one market saturates, patent monetizers may seek new targets, making life sciences a likely next frontier. Universities are not traditional NPEs, but their patent inventories could be transferred to NPEs or used in partnership with them. Protecting innovation requires strengthening the patent and litigation systems so parties cannot extract value far beyond their legitimate rights.

Data Points: Share of patent lawsuits filed by NPEs in 2007: About 25% - Used to show the early rise of non-practicing entity litigation activity. Share of patent lawsuits filed by NPEs in 2012: More than half - Illustrates how quickly NPE-initiated lawsuits expanded within five years. Universities studied: 5 major research universities - UC system, University of Texas system, MIT, Caltech, and University of South Florida were reviewed for potentially weaponizable patents. Potentially deployable patents found: Dozens - Feldman says the university patent review identified dozens of patents that could be used against existing biopharma products.

Pivotal Quotes: "The non-practicing entity train is barreling down the track." — Robin Feldman: Describing the rapid growth of patent troll litigation and warning that the problem is escalating. "Life science trolling is in its infancy and it's predictable." — Robin Feldman: Explaining why universities and policymakers should act now before the problem becomes entrenched. "Dancing with patent trolls could be a risky business for universities." — Robin Feldman: Warning universities that partnering with patent monetizers could create reputational and financial exposure.

Implications: Biopharma companies should prepare for more aggressive patent monetization tactics, especially around high-value, late-stage products. Universities and policymakers may need tighter controls on patent transfers and litigation incentives to prevent life sciences from becoming the next major troll target.